Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icatibant for Acute HAE Attacks in Japanese Pediatric Patients
NCT04654351Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoints: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAE) up to 6 months and Number of Participants With Injection Site Reactions. Started Jan 2021; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04654351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654351.